The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

It may contain inaccuracies due to the limitations of machine translation. Moderna's COVID-19 vaccine. It showed 94.1% efficacy in Phase 3 clinical trials. The company applied for Emergency Use ...

GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.

To many scientists and doctors, messenger RNA vaccines are an incredible feat of modern medicine. But to top health leaders in the Trump administration, shots made with the technology pose more risks ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Kostaive (zapomeran) mRNA COVID-19 ...

PARIS (Reuters) - France's top health body will on Friday say that recipients of a first dose of AstraZeneca's traditional COVID-19 vaccine who are under 55 should get a second shot with a new-style ...

UK MHRA approves zapomeran mRNA Covid-19 vaccine for immunisation of individuals aged 18 years of age and older: United Kingdom Monday, January 5, 2026, 11:00 Hrs [IST] The Medici ...

Health and Human Services Secretary Robert F. Kennedy Jr. revealed his agency will be cutting funding to mRNA development, calling the vaccine technology "ineffective" and claiming it poses more risks ...

Shares of vaccine maker Moderna dropped more than 4% early Thursday after reports that the Health and Human Services Department was re-evaluating its $590 million contract to develop a bird flu ...